Overview

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Status:
Unknown status

Trial end date:
2020-12-30

Target enrollment:

Participant gender:

Summary

This study is a single-arm, prospective, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus Vinorelbine given as neoadjuvant treatment in Trastuzumab-refractory HER2 positive early stage or locally advanced breast cancer.

Phase:

N/A

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

Trastuzumab
Vinorelbine